Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
MRMereo BioPharma Group plc logo

Mereo BioPharma Group plc (MREO)

NASDAQ Global Market · Currency in USD
$0.28 ▼ -0.01 (-1.98%)
At close: Oct 23, 4:00 PM ET. Market closed.
$0.28 ▼ 0.00 (-0.43%)
After hours: Oct 23, 7:47 PM ET

Summary

Previous Close
$0.29
Open
$0.28
Day's Range
$0.28 – $0.29
52 Week Range
$0.20 – $2.37
Volume
518,695
Avg. Volume
3,243,499
Market Cap
$44.98M
Beta (5Y Monthly)
0.30
PE Ratio (TTM)
--
EPS (TTM)
-$0.17
Earnings Date
Nov 9, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$3.25

Profile: Mereo BioPharma Group plc

Sector
Healthcare
Industry
Biotechnology
Full-time employees
39
CEO
Denise Vera Scots-Knight

Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the company boasts a diverse product pipeline. Its primary oncology asset, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor, is presently undergoing Phase 1b clinical investigation for tumor treatment.

Earnings

Next report: Mon, Nov 9, 2026
EPS estimate -$0.01 · Revenue est. $4.61M
DateEst.Actual
Aug 11, 2026-$0.01-$0.01Beat
May 12, 2026$0.02-$0.01Miss
Mar 19, 2026-$0.01-$0.01Beat
Nov 10, 2025-$0.01-$0.01Miss
Aug 12, 2025-$0.01-$0.02Miss
May 13, 2025-$0.01-$0.02Miss

Analyst view

Consensus price target
$3.25 ▲ +1,053.7%
Range $0.50 – $8.00
Rating: Buy
Buy 63% · Hold 25% · Sell 13%

Get free alerts on MREO and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.